Publications
5532 Results
- Journal / Conference
- Journal of Clinical Oncology 12(10):2078-2085
- Year
- 1994
- Research Committee(s)
- Breast
- Study Number(s)
- SWOG-7827
Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive and estrogen receptor-positive breast cancer patients: A Southwest Oncology Group study
- Journal / Conference
- Annals of Oncology 5(Suppl.5)(#280)
- Year
- 1994
- Research Committee(s)
- Brain
- Study Number(s)
- SWOG-9110
Phase II trial of didemnin B (DNB) in patients (pts) with recurrent or residual malignant gliomas
- Journal / Conference
- Investigational New Drugs 12:259-261
- Year
- 1994
- Research Committee(s)
- Sarcoma
- Study Number(s)
- SWOG-8322
A Southwest Oncology Group phase II evaluation of fludarabine monophosphate in sarcoma.
- Journal / Conference
- Annals of Oncology 5(Suppl.2):S91-S95
- Year
- 1994
- Research Committee(s)
- Lymphoma
- Study Number(s)
- SWOG-8516 (INT-0067)
A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: Results of SWOG-8516 (Intergroup 0067), the national high-priority lymphoma study
- Journal / Conference
- Urology 151(5):238A(#44)
- Year
- 1994
- Research Committee(s)
- Genitourinary
- Study Number(s)
- SWOG-8894 (INT-0105) (EST-2889)
Treatment of histologically confirmed D2 prostate cancer - a comparison of bilateral orchiectomy with or without flutamide (intergroup study 0105)
- Journal / Conference
- Journal of Clinical Oncology 12(10):2060-2065
- Year
- 1994
- Research Committee(s)
- Melanoma
- Study Number(s)
- SWOG-8049
Randomized trial of vitamin A versus observation as adjuvant therapy in high risk primary malignant melanoma: A Southwest Oncology Group study
- Journal / Conference
- Investigational New Drugs 12(2):147-149
- Year
- 1994
- Research Committee(s)
- Genitourinary
- Study Number(s)
- SWOG-8929
Phase II evaluation of merbarone in renal cell carcinoma
- Journal / Conference
- Cancer 75(3):815-820
- Year
- 1994
- Research Committee(s)
- Myeloma
- Study Number(s)
- SWOG-8900
A phaseIII randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma: A Southwest Oncology Group study
- Journal / Conference
- Investigational New Drugs 12:155-157
- Year
- 1994
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- SWOG-8623